Repligen (NASDAQ:RGEN) Shares Gap Down – Here’s What Happened

Repligen Corporation (NASDAQ:RGEN)’s share price gapped down prior to trading on Tuesday. The stock had previously closed at $180.17, but opened at $168.34. Repligen shares last traded at $171.9850, with a volume of 226,902 shares trading hands.

Repligen News Summary

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Third-quarter earnings were $0.53 per share, exceeding the $0.46 analyst consensus and rising from $0.46 a year earlier. Revenue reached $209.3 million, topping estimates of approximately $206.7 million and increasing 10.9% year over year. Repligen Q3 earnings and revenue report
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $844 million-$852 million, implying reported growth of 14.5%-15.5%. Organic third-quarter revenue growth was reported at 12.5%, supporting the company’s outlook for continued demand in bioprocessing. Repligen third-quarter results and guidance
• Positive Sentiment: The completed BioLife acquisition expands Repligen’s cell-therapy offerings and could strengthen its position in a high-growth market, although integration and execution will remain important. BioLife acquisition announcement
• Negative Sentiment: Results included a reported $41.2 million charge, which may be weighing on investor sentiment despite the earnings and revenue beats. The charge raises questions about near-term profitability and acquisition-related costs. Repligen Q3 charge and guidance report
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no meaningful evidence of short-covering demand or bearish positioning. With a valuation near 241 times earnings, the stock may require continued strong growth to sustain investor expectations.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of research analyst reports. Barclays upped their price objective on shares of Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. lifted their target price on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Repligen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Finally, Wells Fargo & Company upped their price target on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $175.71.

Repligen Trading Down 2.7%

The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $177.37 and a two-hundred day moving average price of $144.96. The firm has a market capitalization of $9.90 billion, a price-to-earnings ratio of 239.81, a PEG ratio of 3.23 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.07. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $209.31 million for the quarter, compared to analysts’ expectations of $206.71 million. During the same quarter in the previous year, the company posted $0.46 EPS. The company’s revenue was up 10.9% compared to the same quarter last year. As a group, research analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. ABS Investment Management LLC acquired a new stake in Repligen during the second quarter worth $191,016,000. CoreCap Advisors LLC lifted its stake in shares of Repligen by 1,275.0% in the 3rd quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 255 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Repligen by 35.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 98 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Repligen during the 2nd quarter worth $52,000. Finally, Trust Co. of Vermont acquired a new stake in shares of Repligen during the 2nd quarter worth about $71,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.